VintaBio

VintaBio, Inc. specializes in the development and manufacturing of high-quality viral vectors for gene and cell therapies, leveraging a team whose collective experience spans over a century in the CGT field. Founded by Junwei Sun and Dr. Shangzhen Zhou—key architects of the AAV vectors used in the first FDA-approved gene therapies and the lentiviral vector for the first FDA-approved cell therapy—VintaBio brings deep expertise to an industry that still lacks reliable vector supply. The company operates a state-of-the-art 22,500-square-foot facility in Philadelphia's historic Navy Yards, designed to streamline production and ensure consistency across its product portfolio, which includes viral vectors, vaccines, and an adherent platform. With $64 million in venture capital, VintaBio is positioned to accelerate the commercialization of next-generation therapeutics while maintaining rigorous quality standards.